Rinowel contains Irinotecan Hydrochloride, a camptothecin-derived cytotoxic chemotherapy medicine and topoisomerase I inhibitor used in the treatment of several solid tumors.

Irinotecan is converted in the body to its active metabolite, SN-38, which inhibits topoisomerase I. This interferes with DNA replication and causes DNA damage in susceptible cancer cells, thereby inhibiting their growth and proliferation.

Rinowel is administered by intravenous infusion and is commonly incorporated into combination chemotherapy regimens, particularly for colorectal cancer.

What is Irinotecan Hydrochloride?

Irinotecan Hydrochloride is a topoisomerase I inhibitor belonging to the camptothecin class of anticancer medicines. It interferes with DNA replication in rapidly dividing cells.

It has an established role in treatment protocols for colorectal cancer, including metastatic disease, and may also be used for selected other malignancies according to specialist oncology protocols.

Benefits / Uses

Rinowel (Irinotecan Hydrochloride) may be used as part of specialist chemotherapy protocols for:

• Colorectal cancer
• Metastatic colorectal cancer
• Colon cancer
• Rectal cancer
• Pancreatic cancer in selected combination regimens
• Small cell lung cancer in selected treatment settings
• Other solid tumors according to established oncology protocols

Irinotecan is frequently incorporated into combination regimens such as FOLFIRI for colorectal cancer.

Dosage Guidelines

Irinotecan dosage varies according to the cancer type, treatment regimen, body surface area, liver function, previous treatment, and patient-specific factors.

• Administer by intravenous infusion under qualified oncology supervision.
• Dosage is determined according to the specific chemotherapy protocol.
• Complete blood counts should be monitored regularly because significant neutropenia can occur.
• Patients should be monitored closely for diarrhea, an important potential toxicity of Irinotecan.
• Liver function should be assessed before and during treatment as clinically appropriate.
• Dose modifications may be required following significant toxicity or in patients with hepatic impairment.
• Appropriate management of early-onset and delayed diarrhea should be provided according to the prescribing protocol.

Wholesale & Supply

Rinowel (Irinotecan Hydrochloride Injection) may be supplied for pharmaceutical wholesale, institutional procurement, and export markets, subject to applicable regulatory requirements.

Bulk procurement enquiries may include:

• Available strengths and presentations
• Packaging configuration
• Certificate of Analysis (CoA)
• Batch documentation
• Manufacturing documentation
• Export and shipping documentation

Buying Online

Irinotecan is a prescription chemotherapy medicine and should be sourced through authorized pharmaceutical distributors, hospitals, or licensed healthcare channels.

It should be prepared, handled, and administered by qualified healthcare professionals experienced in cytotoxic medicines.

Reviews

Individual responses to Irinotecan vary according to cancer type, disease stage, treatment regimen, previous therapy, and patient-specific factors. Treatment response and tolerability should be evaluated by the treating oncology team.

Quality Assurance

Rinowel (Irinotecan Hydrochloride Injection) should undergo appropriate pharmaceutical quality-control testing according to applicable standards, including relevant testing for identity, potency, purity, sterility, and other formulation-specific quality requirements.

Frequently Asked Questions

What is Rinowel used for?

Rinowel contains Irinotecan Hydrochloride and is primarily used as part of chemotherapy regimens for colorectal cancer, including metastatic colorectal cancer.

What type of medicine is Irinotecan?

Irinotecan is a camptothecin-derived cytotoxic chemotherapy medicine and topoisomerase I inhibitor.

How does Irinotecan work?

Irinotecan inhibits topoisomerase I, interfering with DNA replication and causing DNA damage that inhibits the growth of susceptible cancer cells.

How is Rinowel administered?

Rinowel is administered by intravenous infusion under the supervision of qualified healthcare professionals.

Is Irinotecan used for colorectal cancer?

Yes. Irinotecan is an important component of several chemotherapy regimens used for colorectal cancer, including combination regimens such as FOLFIRI.

What are the common side effects of Irinotecan?

Potential adverse effects include diarrhea, neutropenia, anemia, nausea, vomiting, fatigue, abdominal discomfort, and reduced appetite.

Why is diarrhea important with Irinotecan treatment?

Irinotecan can cause both early-onset and delayed diarrhea. Severe diarrhea can result in dehydration and other complications and requires prompt medical management.

Does Irinotecan require blood-count monitoring?

Yes. Regular complete blood counts are important because Irinotecan can cause significant neutropenia and other forms of bone-marrow suppression.

Who should administer Rinowel?

Rinowel should be prescribed and administered by qualified healthcare professionals experienced in cancer chemotherapy.

Conclusion

Rinowel (Irinotecan Hydrochloride Injection) is a camptothecin-derived cytotoxic chemotherapy medicine and topoisomerase I inhibitor used particularly in treatment protocols for colorectal cancer. By interfering with DNA replication, Irinotecan damages susceptible cancer cells and inhibits their proliferation. It is frequently used in combination regimens such as FOLFIRI. Because significant neutropenia and diarrhea can occur, treatment requires specialist oncology supervision and appropriate monitoring.